Iovance Posts Record $99M Q2 Revenue, 56% Gross Margin; FDA Grants Fast Track for Sarcoma
IOVA has more than doubled off its 52-week low of $1.76.
Summary
Iovance delivered record Q2 revenue of ~$99M, up 66% YoY, driven by strong U.S. Amtagvi demand. Gross margin hit 56%, reflecting manufacturing efficiencies and cost discipline. The company is reviewing its FY2026 revenue guidance of $350-$370M and will update in Q3, signaling potential upside. Separately, the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas, expanding the pipeline. This follows the recent Australian approval and IND clearance for IOV-5001, reinforcing commercial and regulatory momentum.
At the time of this announcement, IOVA was trading at $5.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $1.76 to $5.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.